Summary
A prospective study was performed in patients treated with cisplatin to evaluate the occurrence and degree of central, peripheral and autonomic neuropathy and to determine the most accurate method to study this neuropathy. Twelve patients were examined before, during and after treatment. Evaluation included neurologic examination, conventional nerve conduction studies of the median and peroneal nerves and short latency somatosensory evoked potentials (SSER) after median and tibial nerve stimulation. Valsalva maneuvers before and during treatment were performed in 11 patients. Symptoms of peripheral neuropathy paralleled clinical signs. Conventional nerve conduction studies did not seem to be more accurate than clinical examination in determining peripheral neuropathy. SSER appeared to be the most sensitive method for the detection of peripheral nerve impairment. A slowing of central conduction velocity occurred after cumulative doses of 200–400 mg/m2 as measured by SSER. In two patients also some involvement of the autonomic nerves was suggested.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rozencweig M, Von Hoff DD, Slavik M, Muggia FM: Cisdiamminedichloroplatinum (II). A new anticancer drug. Ann Int Medicine 86: 803–812, 1977
Cisplatin (editorial): Lancet 1: 374–375, 1982
Kedar A, Cohen ME, Freeman AL: Peripheral neuropathy as a complication of cisdichlorodiammineplatinum (II) treatment: A case report. Cancer Treat Rep 62: 819–821, 1978
Thompson SW, Davis LAE, Kornfeld M, Hilgers RD, Standefer JC: Cisplatin neuropathy: clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 54: 1269–1275, 1984
Hadley D, Herr HW: Peripheral neuropathy associated with cisdichlorodiammineplatinum (II) treatment. Cancer 44: 2026–2028, 1979
Roelofs RJ, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938, 1984
Ongerboer de Visser BW, Tiessens G: Polyneuropathy induced by cisplatin. Prog exp Tumor Res 29: 190–196, 1985
Mollman JE, Hogan WM, Glover DJ, McCluskey LF: Unusual presentation of cis-platinum neuropathy. Neurology 38:488–490, 1988
Eeles R, Tait DM, Peckham MJ: Lhermitte's signs as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep 70: 905–907, 1986
Dewar J, Lunt H, Abernethy DA, Dady P, Haas LF: Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry 49: 96–99, 1986
Walther PJ, Rosbitch E, Bullard DE: The development of Lhermitte's sign during cisplatin chemotherapy. Cancer 60: 2170–2172, 1987
Gautier-Smith PC: Lhermitte's sign in subacute combined degenetation of the cord. J Neurol Neurosurg Psychiatry 36:861–863, 1972
Rosenfeld CS, Broder LE: Cisplatin-induced autonomic neuropathy. Cancer Treat Rep 68: 659–660, 1984
Cohen SC, Mollman JE: Cisplatin-induced gestric paresis. J Neurol Oncol 5: 237–240, 1987
Daugaard GK, Petrera J, Trojaburg W: Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol Scand 76: 86–93, 1987
Ludin HP: Electromyography in Practice. Georg Thieme Verlag, Stuttgart, 1980
Cho ES: Toxic effects of adriamycin in the ganglia of the peripheral nervous system: a neuropathological study. J Neuropath Exp Neurol 36: 907–915, 1977
Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Sem Oncol 9: 103–130, 1982
Levin AB: A simple test of cardiac function based upon the heart rate changes induced by the Valsalva maneuver. Am J Cardiol 18: 90–99, 1966
Hansen SW: Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. Br Med J 300: 511–512, 1990
Cowan JD, Kies MS, Roth JL, Joyce RP: Nerve conduction studies in patients treated with cis-diamminedochloroplatinum (II): a preliminary report. Cancer Treat Rep 64: 1119–1122, 1980
Riggs JF, Ashraf M, Snyder RD, Gurmann L: Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 23: 92–94, 1988
Clark AW, Parhad IM, Griffin JW, Price DL: Neurotoxicity pf cisplatinum: pathology of the central and peripheral nervous systems. Neurology 30: 429, 1980
Walsh TJ, Clark AW, Parhad IM, Green WR: Neurotoxix effects of cisplatin therapy. Arch Neurol 39: 719–720, 1982
Von Hoff DD, Reichert CM, Cuneo R, Reddick R, Callagher M, Rozencweig M: Demyelination of peripheral nerves associated with cis-diamminedochloroplatinum (II) (DDP) therapy. Proc Am Ass Cancer Res 20: 91, 1979
Tomiwa K, Nolan C, Cavanagh JB: The effects of cisplatin on rat spintal ganglia. A study by light and electron microscopy and by morphometry. Acta Neuropathol 69: 295–308, 1986
Griffin JW, Watson DF: Axonal transport in neurological disease. Ann Neurol 23: 3–13, 1988
Mollman JE, Glover DJ, Hogan WM, Furman RE: Cisplatin neuropathy. Risk factors, prognosis and protection by protection by WR-2721. Cancer 61: 2192–2195, 1988
Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, Elderson A, Boogerd W, Heimans JJ, Vries EP, van Houwelingen JC, Jennekens FGI, Gispen WH, Neyt JP: Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. N Eng J Med 322: 89–94, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boogerd, W., ten Bokkel Huinink, W.W., Dalesio, O. et al. Cisplatin induced neuropathy: Central, peripheral and autonomic nerve involvement. J Neuro-Oncol 9, 255–263 (1990). https://doi.org/10.1007/BF02341156
Issue Date:
DOI: https://doi.org/10.1007/BF02341156